Oncolytics Biotech Inc T.ONC

Merck USA (MSD) acquires Phase 2 blood cancer co - US$1.35B

[Noteable]

Merck USA (MSD) acquires single indication product Phase 2 blood cancer company Imago for US$1.35 Billion

The blood cancer market is reported to be 1/10th the size of solid tumors.

https://www.businesswire.com/news/home/20221121005295/en/Merck-to-Acquire-Imago-BioSciences-Inc.

[Noteable]

November 21, 2022 ... "Merck & Co. has opened its wallet wide to buy a midphase treatment for life-threatening diseases of the bone marrow..." https://www.fiercebiotech.com/biotech/merck-inks-14b-blood-cancer-biotech-buyout-muscle-market-target-bristol-myers-novartis

[Noteable]

With Merck USA paying up big for Phase 2 single indication blood cancer - this confirms that Big Pharma is in significant need of innovative cancer drugs to face off the challenge of a looming patent cliff by 2025 and every new cancer drug in development is on the table for their immediate acquisition, more particularly immuno-oncology platform therapy drugs like ONCY'S pelareorep which can be

[Lesalpes29]

Without Parsons and Rigby in house I would be completly out! Something positive in the coming weeks is clearly possible. I'm Not surprise to see the price going down. Some are taking profit, maybe a little bit of manipulation of course... Manipulation could be very high particularly when negociations are in full force! We will see...

[Noteable]

This is an example of Big Pharma beginning to "pull the trigger" on M&A deals.

[Noteable]

December 12, 2022 - Merck known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Imago Biosciences Inc. On Nov. 21, 2022, Merck announced that it had entered into a definitive agreement to acquire Imago. https://www.biospace.com/article/releases/merck-begins-tender-offer-to-acquire